Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2019. The document serves as a transaction notification regarding a specific share acquisition by a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a single transaction event rather than a financial performance report.
- Transaction Type: Acquisition of Ordinary Shares via dividend re-investment.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £15.7335 per share.
- Transaction Volume: 19 shares.
- Transaction Date: April 11, 2019.
- Exchange: London Stock Exchange (XLON).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document notes an administrative error that caused a delay in the initial notification of the transaction by the plan provider.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is strictly a compliance notification regarding the acquisition of shares by Ms. S Jackson, SVP, Global Communications & CEO Office.
Investor Verification Points
- Verify the identity of the PDMR (Ms. S Jackson) and confirm the transaction aligns with the company's dividend re-investment plan.
- Note that the transaction occurred on April 11, 2019, but was reported in this October 2019 filing due to an administrative delay.
- Confirm that this filing does not impact the company's overall share count or financial statements given the minimal volume (19 shares).